ATE323153T1 - Sphingosinekinase - Google Patents

Sphingosinekinase

Info

Publication number
ATE323153T1
ATE323153T1 AT00926537T AT00926537T ATE323153T1 AT E323153 T1 ATE323153 T1 AT E323153T1 AT 00926537 T AT00926537 T AT 00926537T AT 00926537 T AT00926537 T AT 00926537T AT E323153 T1 ATE323153 T1 AT E323153T1
Authority
AT
Austria
Prior art keywords
present
mimetics
analogues
derivatives
chemical equivalents
Prior art date
Application number
AT00926537T
Other languages
English (en)
Inventor
Stuart Maxwell Pitson
Brian Wolff Wattenberg
Pu Xia
Andrea Richard James D
Jennifer Ruth Gamble
Mathew Alexander Vadas
Original Assignee
Johnson & Johnson Pharm Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ0339A external-priority patent/AUPQ033999A0/en
Priority claimed from AUPQ1504A external-priority patent/AUPQ150499A0/en
Application filed by Johnson & Johnson Pharm Res filed Critical Johnson & Johnson Pharm Res
Application granted granted Critical
Publication of ATE323153T1 publication Critical patent/ATE323153T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00926537T 1999-05-13 2000-05-12 Sphingosinekinase ATE323153T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ0339A AUPQ033999A0 (en) 1999-05-13 1999-05-13 Novel therapeutic molecules and uses thereof
AUPQ1504A AUPQ150499A0 (en) 1999-07-08 1999-07-08 Novel therapeutic molecules and uses thereof-II

Publications (1)

Publication Number Publication Date
ATE323153T1 true ATE323153T1 (de) 2006-04-15

Family

ID=25646054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00926537T ATE323153T1 (de) 1999-05-13 2000-05-12 Sphingosinekinase

Country Status (11)

Country Link
US (3) US6730480B1 (de)
EP (1) EP1192247B9 (de)
JP (1) JP2002543831A (de)
KR (1) KR100798375B1 (de)
AT (1) ATE323153T1 (de)
CA (1) CA2372541A1 (de)
DE (1) DE60027295T2 (de)
DK (1) DK1192247T3 (de)
ES (1) ES2261200T3 (de)
NZ (1) NZ515132A (de)
WO (1) WO2000070028A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
JP2003512072A (ja) * 1999-10-28 2003-04-02 ワーナー−ランバート・カンパニー ヒトスフィンゴシンキナーゼ遺伝子
AU3828301A (en) * 2000-02-14 2001-08-27 Curagen Corp Novel sphingosine kinases
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US20080279841A1 (en) * 2000-06-28 2008-11-13 Medvet Science Pty Ltd. Novel Therapeutic Molecular Variants And Uses Thereof
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
CA2432978C (en) 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20050100547A1 (en) * 2001-06-07 2005-05-12 Pu Xia Etal Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
JP4667749B2 (ja) * 2002-01-17 2011-04-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド スフィンゴ脂質代謝および／またはシグナル伝達の調節のための組成物および方法
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
JP2005526809A (ja) * 2002-03-28 2005-09-08 メドベット サイエンス ピーティーワイ． リミティッド 細胞活性を調節する方法
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
AU2006299417A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
PL2087002T3 (pl) 2006-10-27 2015-02-27 Lpath Inc Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8778614B2 (en) 2010-08-24 2014-07-15 Enzo Life Sciences, Inc. Assays for detecting modified compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (en) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
US6525174B1 (en) * 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
CA2329124A1 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
GB9816030D0 (en) * 1998-07-22 1998-09-23 Smithkline Beecham Plc Novel compounds
AU2899900A (en) * 1999-03-02 2000-09-21 Nps Allelix Corp. Cloned human sphingosine kinase homologues
JP2002538827A (ja) * 1999-03-18 2002-11-19 インサイト・ファーマスーティカルズ・インコーポレイテッド 細胞内リン酸化反応のレギュレータ
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

Also Published As

Publication number Publication date
US20040132053A1 (en) 2004-07-08
WO2000070028A1 (en) 2000-11-23
US6730480B1 (en) 2004-05-04
US7112427B2 (en) 2006-09-26
NZ515132A (en) 2005-01-28
EP1192247B9 (de) 2007-10-31
EP1192247A4 (de) 2003-05-28
JP2002543831A (ja) 2002-12-24
EP1192247A1 (de) 2002-04-03
CA2372541A1 (en) 2000-11-23
DE60027295D1 (de) 2006-05-24
US20070071752A1 (en) 2007-03-29
DE60027295T2 (de) 2007-01-18
ES2261200T3 (es) 2006-11-16
DK1192247T3 (da) 2006-07-31
KR100798375B1 (ko) 2008-01-28
KR20020000805A (ko) 2002-01-05
EP1192247B1 (de) 2006-04-12

Similar Documents

Publication Publication Date Title
DE60027295D1 (de) Sphingosinekinase
DK0910647T3 (da) Human DNase i hyperaktive varianter
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
TW200407425A (en) Human coagulation factor VII polypeptides
AU2003266214A1 (en) Human coagulation factor vii polypeptides
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
PY0104899A (es) Las 5-alquilpirido [2,3-d] pirimidinas son inhibidoras de las cinasas de tirosina y que dependen de la ciclina
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
EP1100815A4 (de) Von protease typ ii spaltbares peptid
DE60327936D1 (de) Modulatoren von ship-1
ATE340257T1 (de) Histonedeacetylase 9
DK1082423T3 (da) Cyclin E2-gener og -proteiner
PL374550A1 (en) Il-17 like molecules and uses thereof
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
EP1383871A4 (de) Isolierte menschliche enzymproteine, menschliche enzymproteine codierende nukleinsäuremoleküle sowie verwendungen davon
SE9703287D0 (sv) Peptides
MXPA02012924A (es) Nuevas variantes moleculares terapeuticas y sus usos.
EP1383908A4 (de) Isolierte menschliche enzymproteine, menschliche enzymproteine codierende nukleinsäuremoleküle sowie verwendungen davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1192247

Country of ref document: EP